Therapeutic potential of loxoprofen: new possibilities of symptomatic therapy of pain and inflammatory syndrome in upper respiratory tract infections. A review

Acute respiratory infections are a heterogeneous group of diseases that combine damage to both the upper (in most cases) and lower respiratory tract. The incidence of this pathology and the number of visits to doctors and economic losses tend to increase annually. Strains of pathogens with pronounced pathogenicity and having mechanisms of "hiding" from the immune response of the human body play a significant role in the deterioration of the epidemiological situation. Increasingly, there are blurred and atypical clinical pictures of acute respiratory pathology, which complicate the etiological diagnosis and, accordingly, adequate treatment. The problem of unjustified prescription of antibacterial therapy in the case of viral etiology of the process remains difficult and urgent, as a result of which there is an increase in antibiotic resistance of pathogens. Many patients underestimate the importance of pathogenetic and symptomatic therapy. The article discusses the issues of modern diagnosis and therapy of patients with acute diseases of the upper respiratory tract, the role and place of the systemic nonsteroidal anti-inflammatory drug loxoprofen in such patients.